This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
10-03 :: March 2010

nanotimes

Companies

Facts

B

T Pharma, a biopharmaceutical company deve- loping innovative immunotherapies to prevent

cancers caused by the human papillomavirus (HPV), has raised EUR13.1 million in additional funding and

changed its name to Genticel. AGF Private Equity

led the round.

http://www.genticel.com

C

tools RFP-Trap®

hromoTek, a company specializing in bioima- ging reagents, has launched the bioimaging and GFP-Booster. RFP-Trap®

is

used to identify and pull down interaction partners of proteins tagged with RFP (red fluorescent protein) and GFP-Booster restores or increases the GFP (green fluorescent protein) signal in super-resolution micro- scopy. RFP-Trap®

is a versatile tool for biochemical

and cell biological analysis of RFP-tagged fusion proteins in pull down assays (a frequently used in vitro method used to determine physical interaction between two or more proteins).

http://www.chromotek.com

T

he Dow Chemical Company‘s (NYSE:DOW)

North American Technical Service and Global

Research and Development Center for packaging adhesives and coatings will move to Buffalo Gro- ve, Illinois in early April 2010. The expanded Tech Service and R&D Center represents a significant step forward in the company’s commitment to enhance customer support and new product deve- lopment. Buffalo Grove is located in close proximity to Chicago’s O’Hare Airport. The facility has been located in Elgin, Illinois, USA.

http://www.rohmhaas.com

E

purex Films GmbH & Co. KG, a subsidiary of Bayer MaterialScience, will be marketing film

products formerly sold as Walopur® Walotex®

, Platilon® and under the common trade name Platilon® .

“This move will enable Epurex Films, as one of the leading European manufacturers of thermoplastic polyurethane (TPU) films, to work more openly and effectively with its customers, to further increase awareness of the name Platilon®

21

and to strengthen its

position on the international markets,” says Rüdiger Heins, Head of Sales and Marketing at Epurex Films.

Examples of demanding applications include breatha- ble but watertight membranes for outdoor clothing, special plasters that create a healthy wound climate and encourage rapid healing, and intermediate layers for bulletproof glass.

http://www.functional-films.com

F

lamel Technologies (NASDAQ:FLML) announced its financial results for the fourth quarter and year

ended December 31, 2009. Results during the fourth quarter: • Pfizer exercised the option to license the Medusa® platform for development of an improved intrave- nous formulation of an already-marketed molecule acquired in its merger with Wyeth;

• The Company signed new feasibility studies app- lying the Medusa®

with two top-ten pharmaceutical companies;

• The Company announced that the Agence Na- tionale de Recherche sur le SIDA et les Hépatites Virales (ANRS) initiated a twelve week study com- paring two dosage forms of IFN-alpha XL plus riba- virin versus Peg-Intron® Hepatitis C patients.

platform to three new molecules

plus ribavirin in genotype 1 Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69